Nov 08, 2024 05:05 PM
PODCAST
Caixin Deep Dive: Untangling AstraZeneca’s China Fraud Case
Nov.08.2024
The British pharmaceutical giant falsified patient test results to secure insurance coverage for its cancer drug in an effort to boost sales, but the alleged misconduct ended up benefiting some patients
00:00/00:00
Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story:
Cover Story: How AstraZeneca’s China Fraud Was About More Than Greed
Zhu Xi contributed to this podcast.
Share this article
Open WeChat and scan the QR code
MORE WAYS TO LISTEN
MOST POPULAR
- 1Chinese Courts Rule Companies Cannot Fire Workers Simply to Replace Them With AI
- 2China Names Unlicensed Firms Misusing Financial Labels
- 3China Southern Orders Airbus Jets Worth $21 Billion
- 4In Depth: PwC’s Evergrande Crisis Deepens With Record Hong Kong Settlement and Criminal Probes
- 5China Orders Reversal of Meta’s $2 Billion Manus Deal
SPONSORED
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas
Sign in with Google
Sign in with Facebook
Sign in with 财新